A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...
Major, fresh-for-2025 updates on the Rivian R1S SUV and R1T pickup truck dropped this week. Open our comprehensive first-drive review in another tab to check out later if you haven’t! One of the ...
At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections. Krina Patel, MD, MSc, associate professor in ...
ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
JAMES CITY COUNTY, Va. (WAVY) – CEL Critical Power has invested $5.225 million to open its first facility in James City County to produce power for data centers. The Dublin-based manufacturer plans to ...
Cel Critical Power to bring 250 jobs to James City County with new U.S. facility, says Gov. Youngkin
JAMES CITY COUNTY, Va. — CEL Critical Power, a global provider of power solutions, will invest $5.2 million to open its first American manufacturing facility in James City County, Governor Glenn ...
More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...
CEL-SCI Corporation (NYSE:CVM) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell ...
Arcellx, Inc. (ACLX) is making significant progress in the development of its lead CAR-T cell therapy, anitocabtagene Autoleucel (anito-cel), for the treatment of patients with relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results